nonresponse to the first TNFi In cases of nonresponse (primary or secondary), the panel recommended against switching to the biosimilar of the first TNFi (e.g., switching from originator infliximab to infliximab-dyyb), as the clinical response would not be expected to be different. The panel also recommended against the addition of sulfasalazine or methotrexate to TNFi in cases of nonresponse to TNFi, judging any benefit would likely be marginal. The addition of sulfasalazine could be